ClinicalTrials.gg
RecruitingNCT07275840Updated Jan 8, 2026

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

A Phase 2 interventional study of IBI302 8mg dose in Neovascular Age-related Macular Degeneration, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Recruiting at 1 site in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
800
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Planned enrollment
3rd of 91
800 · median 62
Started
2025
with 14 others
Phase 2
14 of 106
4 open now
Primary completion
2026-08
later than 19 of 42 live
Registered
95th of 106
by date

Among the 106 studies in Macular Degeneration with a site in China, this one is the 3rd largest by planned enrollment of the 91 interventional ones that give a count, is one of 15 that started in 2025, is one of 14 in phase 2, reaches primary completion later than 19 of the 42 other live ones, and was the 95th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have signed an form before participating in the research.
  2. Male or female individuals aged 50 or above at the time of signing the informed consent form;
  3. Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
  4. At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).

Exclusion criteria

Exclusion Criteria:

  1. According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results;
  2. The study eye has uncontrollable glaucoma;
  3. There is an active intraocular or periocular infection or inflammation in either eye;
  4. The non-study eye has severe visual function disorders;
  5. Within 90 days before baseline, the study eye had received anti-VEGF treatment;
  6. Within 90 days before baseline, the study eye had received anti-complement treatment;
  7. At any time before baseline, the study eye had received IBI302 treatment;
  8. Uncontrollable hypertension;
  9. (HbA1c) > 10.0% within 28 days prior to screening;
  10. Other exclusion criteria set by protocol.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    IBI302 8mg dose 8mg

    Drug: IBI302 8mg/Intravitreal injection

    Drug: IBI302 8mg dose

Interventions

  • 8 mg IBI302 will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of participants whose best corrected visual acuity (BCVA) of the study eye decreased by less than 15 letters from baseline as measured by the visual acuity chart in the early treatment diabetic retinopathy study (ETDRS) at week 52

    Time frame: Week52

Secondary outcomes

  1. The changes in BCVA from baseline at each visit

    Time frame: Baseline,Weeks 4,8,12,16,20,24,28,32,36,40,44,48 and 52

  2. Proportion of patients with BCVA improvement of ≥0, ≥5, ≥10, and ≥15 ETDRS letters from baseline at week 52

    Time frame: Week52

  3. Proportion of participants with a decrease in BCVA of >0, ≥5, ≥10, and ≥15 ETDRS letters from baseline at week 52

    Time frame: Week52

  4. The change in central subfield thickness of the macula measured by OCT from the baseline at week 52

    Time frame: Week52

  5. Proportion of participants with IRF/SRF/Pigment epithelial detachment (PED) on OCT at Week 52

    Time frame: Week52

  6. Change in choroidal neovascularization (CNV) area on fundus fluorescein angiography (FFA) at week 52 compared to baseline

    Time frame: Week52

  7. Change in CNV leakage area on FFA at week 52 compared to baseline

    Time frame: Week52

  8. Proportion of participants with new-onset MA on OCT at Week 52

    Time frame: Week52

  9. Proportion of new-onset fibrosis on color fundus photography (CFP) at Week 52

    Time frame: Week52

  10. Change in MA area on OCT from baseline at Week 52

    Time frame: Week52

  11. Change in fibrosis area and maximum lesion diameter on CFP from baseline at Week 52

    Time frame: Week52

  12. The incidence rate, correlation with the studied drugs, and severity of ocular and systemic adverse events (AE), treatment emergent adverse events (TEAE), and serious adverse events (SAE)

    Time frame: From baseline through Week 52

  13. The production of anti-drug antibodies in the serum

    Time frame: Day0、Week4、Week16、Week32、Week48、Week52

07

Study locations

1 of 1 sites recruiting
  • Shanghai general hospital
    Shanghai, Shanghai Municipality P. R. China 200080, China
    Recruiting
    • Xiaodong Sun, Doctor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2026, 8 months after the start.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's planned 8 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 10, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07275840
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Dec 5, 2025
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Yating Liu
Contact
yating.liu@innoventbio.com
86 15821084695

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI302

Start the discussion